NasdaqGM:APEN

Stock Analysis Report

Executive Summary

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices.

Snowflake

Fundamentals

Mediocre balance sheet and slightly overvalued.

Risks

  • Apollo Endosurgery has significant price volatility in the past 3 months.
  • Apollo Endosurgery is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Apollo Endosurgery's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

NasdaqGM:APEN

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-53.0%

NasdaqGM:APEN

8.7%

US Medical Equipment

1.7%

US Market

APEN underperformed the Medical Equipment industry which returned 8.7% over the past year.

APEN underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

APENIndustryMarket
7 Day0%-1.2%1.2%
30 Day4.0%1.4%4.9%
90 Day-7.1%4.8%3.7%
1 Year-53.0%-53.0%9.6%8.7%3.9%1.7%
3 Yearn/a70.8%65.5%47.2%37.7%
5 Yearn/a130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Apollo Endosurgery's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Apollo Endosurgery undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Apollo Endosurgery's share price is below the future cash flow value, and at a moderate discount (> 20%).

Apollo Endosurgery's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Apollo Endosurgery is loss making, we can't compare its value to the US Medical Equipment industry average.

Apollo Endosurgery is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Apollo Endosurgery, we can't assess if its growth is good value.


Price Based on Value of Assets

Apollo Endosurgery is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Apollo Endosurgery expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-1.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Apollo Endosurgery's revenue is expected to grow significantly at over 20% yearly.

Apollo Endosurgery is not considered high growth as it is expected to be loss making for the next 1-3 years.

Apollo Endosurgery's revenue growth is expected to exceed the United States of America market average.

Unable to compare Apollo Endosurgery's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Apollo Endosurgery's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Apollo Endosurgery will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Apollo Endosurgery performed over the past 5 years?

-4.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Apollo Endosurgery does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Apollo Endosurgery's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Apollo Endosurgery's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Apollo Endosurgery has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Apollo Endosurgery has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Apollo Endosurgery improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Apollo Endosurgery's financial position?


Financial Position Analysis

Apollo Endosurgery is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Apollo Endosurgery's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Apollo Endosurgery's level of debt (187.7%) compared to net worth is high (greater than 40%).

Unable to establish if Apollo Endosurgery's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Apollo Endosurgery has sufficient cash runway for 1.1 years based on current free cash flow.

Apollo Endosurgery has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.1% each year.


Next Steps

Dividend

What is Apollo Endosurgery's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Apollo Endosurgery's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Apollo Endosurgery's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Apollo Endosurgery has not reported any payouts.

Unable to verify if Apollo Endosurgery's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Apollo Endosurgery has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Apollo Endosurgery's salary, the management and board of directors tenure and is there insider trading?

5.2yrs

Average management tenure


CEO

Todd Newton (56yo)

5.2yrs

Tenure

US$1,068,801

Compensation

Mr. Todd Newton has been the Chief Executive Officer of Apollo Endosurgery, Inc. since July 1, 2014. Mr. Newton served as the Chief Operating Officer and Chief Financial Officer of ArthroCare Corporation f ...


CEO Compensation Analysis

Todd's remuneration is higher than average for companies of similar size in United States of America.

Todd's compensation has increased whilst company is loss making.


Management Age and Tenure

5.2yrs

Average Tenure

55yo

Average Age

The average tenure for the Apollo Endosurgery management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

5.3yrs

Average Tenure

56yo

Average Age

The tenure for the Apollo Endosurgery board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$88,35014 May 19
Todd Newton
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares25,000
Max PriceUS$3.53
SellUS$750,00001 Jan 19
Stonepine Capital Management LLC
EntityCompany
Shares250,000
Max PriceUS$3.00
SellUS$1,500,00029 Dec 18
Stonepine Capital Management LLC
EntityCompany
Shares500,000
Max PriceUS$3.00
BuyUS$195,92421 Nov 18
Stonepine Capital Management LLC
EntityCompany
Shares57,430
Max PriceUS$3.61
BuyUS$1,500,00006 Nov 18
Stonepine Capital Management LLC
EntityCompany
Shares300,000
Max PriceUS$5.00

Ownership Breakdown


Management Team

  • Sydney Chung

    Co-Founder and Innovation Partner

    • Tenure: 0yrs
  • Jay Pasricha

    Co-Founder

    • Tenure: 14.7yrs
  • Rob Hawes

    Co-Founder and Innovation Partner

    • Tenure: 0yrs
  • Chris Gostout (68yo)

    Co-Founder & Chief Medical Officer

    • Tenure: 0yrs
    • Compensation: US$1.16m
  • Sergey Kantsevoy

    Co-Founder and Innovation Partner

    • Tenure: 0yrs
  • Anthony Kalloo

    Co-Founder and Innovation Partner

    • Tenure: 0yrs
  • Peter Cotton

    Co-Founder and Innovation Partner

    • Tenure: 14.7yrs
  • Stefanie Cavanaugh (54yo)

    CFO, Treasurer & Secretary

    • Tenure: 4.5yrs
    • Compensation: US$520.72k
  • Todd Newton (56yo)

    CEO & Director

    • Tenure: 5.2yrs
    • Compensation: US$1.07m
  • Bret Schwartzhoff (46yo)

    Vice President

    • Tenure: 4.8yrs
    • Compensation: US$343.00k

Board Members

  • John Barr (62yo)

    Chairman of the Board

    • Tenure: 0.3yrs
  • Matt Crawford (53yo)

    Director

    • Tenure: 13.7yrs
  • Bill McClellan (59yo)

    Director

    • Tenure: 5.3yrs
    • Compensation: US$106.10k
  • Adrian Park

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Mark Talamini

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Todd Newton (56yo)

    CEO & Director

    • Tenure: 5.2yrs
    • Compensation: US$1.07m
  • Santiago Horgan

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Bruce Robertson (56yo)

    Director

    • Tenure: 12.7yrs
  • Jay Redan

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Steve McCarus

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Apollo Endosurgery, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Apollo Endosurgery, Inc.
  • Ticker: APEN
  • Exchange: NasdaqGM
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$71.173m
  • Shares outstanding: 20.93m
  • Website: https://www.apolloendo.com

Number of Employees


Location

  • Apollo Endosurgery, Inc.
  • 1120 South Capital of Texas Highway
  • Building 1
  • Austin
  • Texas
  • 78746
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APENNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2016
HQ8FDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2016

Biography

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing S ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 01:26
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.